Agenda

Session Introduction

Reshma L. Mahtani, DO

‍

Risk-Based Strategies for Treatment of Early Stage HER2+ BC

Chau T. Dang, MD

‍

Audience Q&A

Chau T. Dang, MD

‍

Promising Biomarkers in HER2+ BC

Nadine M. Tung, MD

‍

Audience Q&A

Nadine M. Tung, MD

‍

Revolutionizing Treatment: Potentially Practice Changing Trials in Early Stage HER2 BC

Ana C. Sandoval Leon, MD

‍

Audience Q&A

Ana C. Sandoval Leon, MD